Literature DB >> 16759116

Synthesis, structural reassignment, and biological activity of type B MAO inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core.

Raphaël Frédérick1, Willy Dumont, Frédéric Ooms, Lindsey Aschenbach, Cornelis J Van der Schyf, Neal Castagnoli, Johan Wouters, Alain Krief.   

Abstract

The synthesis and enzyme inhibitor properties of reversible type B monoamine oxidase inhibitors are described. These compounds belong to the 5H-indeno[1,2-c]pyridazine family and possess a hydrophobic benzyloxy or 4,4,4-trifluorobutoxy side chain which, in contrast to a previous assignment, has been unambiguously located at C(8) of the heterocyclic moiety. Investigation of the regioisomeric structures establishes that substitution of the 5H-indeno[1,2-c]pyridazin-5-one core at C(7) vs C(8) dramatically influences the MAO-inhibiting properties of these compounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759116     DOI: 10.1021/jm051091j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

Review 1.  The molecular diversity scope of 1,3-indandione in organic synthesis.

Authors:  Shima Asadi; Ghodsi Mohammadi Ziarani
Journal:  Mol Divers       Date:  2015-05-10       Impact factor: 2.943

2.  Construction of Dispiro-Indenone Scaffolds via Domino Cycloaddition Reactions of α,β-Unsaturated Aldimines with 2-Arylidene-1,3-indenediones and 2,2'-(Arylmethylene)bis(1,3-indenediones).

Authors:  Wen-Juan Yang; Hui-Lin Fang; Jing Sun; Chao-Guo Yan
Journal:  ACS Omega       Date:  2019-08-07

3.  Synthesis of diverse spiro-imidazo pyridine-indene derivatives via acid-promoted annulation reaction of bindone and heterocyclic ketene aminals.

Authors:  Shima Nasri; Mohammad Bayat; Fatemeh Rostami Miankooshki
Journal:  Sci Rep       Date:  2022-07-22       Impact factor: 4.996

4.  Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs.

Authors:  Jens Hagenow; Stefanie Hagenow; Kathrin Grau; Mohammad Khanfar; Lena Hefke; Ewgenij Proschak; Holger Stark
Journal:  Drug Des Devel Ther       Date:  2020-01-28       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.